DeFinium Therapeutics Inc (DFTX) Stock Price, Quote & News

Company Profile

Definium Therapeutics, Inc., a clinical biopharmaceutical company, develops novel product candidates to treat brain health disorders. The company's lead product candidates DT120, which is in phase 3 for the treatment of generalized anxiety disorder, major depressive disorder, and other brain health disorders; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of autism spectrum disorder. The company was formerly known as Mind Me...

Industry: Biotechnology

Sector: Healthcare

Phone: 212 220 6633

Website: definiumtx.com

Address:

One World Trade Center, Suite 8500, New York, United States

RarelyRight Mar. 20 at 5:10 PM

$DFTX Wondering if I should trim and move to $CMPS or $ATAI.

4 · Reply

ZackScott Mar. 20 at 4:02 PM

$DFTX

0 · Reply

CuriousChimps Mar. 20 at 4:01 PM

$DFTX tank part 2

0 · Reply

BobbyCucumber Mar. 20 at 2:47 PM

$DFTX

0 · Reply

rajin11 Mar. 19 at 7:50 PM

$DFTX over or under $19 this friday?

1 · Reply

Horseman23 Mar. 19 at 7:36 PM

$DFTX

0 · Reply

CuriousChimps Mar. 19 at 6:22 PM

$DFTX tank

1 · Reply

Rocketzz Mar. 19 at 4:48 PM

$DFTX immune from market conditions. Someone has been absolutely stacking these shares the past year. Big things to come

2 · Reply

rajin11 Mar. 19 at 2:49 PM

$DFTX what is max pain here? Trying to learn any good sites?

1 · Reply

stoxx0007 Mar. 19 at 1:37 PM

$DFTX $ATAI $CMPS

0 · Reply

Definium Therapeutics Announces New Employee Inducement Grants

Feb 26, 2026, 9:57 PM EST - 22 days ago

Definium Therapeutics, Inc. (DFTX) Q4 2025 Earnings Call Transcript

Feb 26, 2026, 4:01 PM EST - 23 days ago

Definium Therapeutics Reports Full-Year 2025 Financial Results and Business Updates

Feb 24, 2026, 7:01 AM EST - 25 days ago

Definium Therapeutics to Participate at Upcoming Investor Conferences

Feb 19, 2026, 4:01 PM EST - 4 weeks ago

Definium Therapeutics to Report Full Year 2025 Financial Results on February 26, 2026

Jan 29, 2026, 7:00 AM EST - 7 weeks ago

Definium Therapeutics Appoints Roger Adsett to Board of Directors

Jan 20, 2026, 7:00 AM EST - 2 months ago

Definium Therapeutics Introduces Rerouting Minds, an Educational Campaign Exploring the Potential of Pharmaceutical Lysergide (LSD) in Mental Health Care

Jan 14, 2026, 7:16 PM EST - 2 months ago

Mind Medicine (MindMed) Inc. (MNMD) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

MMED

Jan 13, 2026, 7:00 AM EST - 2 months ago

Definium Therapeutics Common Shares to Trade under New Nasdaq Ticker Symbol “DFTX” Effective January 15, 2026

Jan 12, 2026, 7:00 AM EST - 2 months ago

MindMed Rebrands to Definium Therapeutics, Advancing a Leading Late-Stage Psychiatry Pipeline with Three Phase 3 Readouts Expected in 2026

Dec 18, 2025, 7:01 AM EST - 3 months ago

MindMed to Present at the 44th Annual J.P. Morgan Healthcare Conference

Dec 15, 2025, 4:01 PM EST - 3 months ago

MindMed Announces New Employee Inducement Grant

Dec 1, 2025, 4:01 PM EST - 3 months ago

MindMed Announces New Employee Inducement Grants

Nov 6, 2025, 9:46 PM EST - 4 months ago

Mind Medicine (MindMed) Inc. (MNMD) Q3 2025 Earnings Call Transcript

Nov 6, 2025, 4:01 PM EST - 4 months ago

MindMed Reports Q3 2025 Financial Results and Business Updates

Nov 5, 2025, 7:01 AM EST - 4 months ago

MindMed to Participate in Upcoming Investor Conferences

Nov 3, 2025, 7:01 AM EST - 4 months ago

Mind Medicine (MindMed) Inc. Announces Closing of Approximately $259 Million Public Offering, Including Full Exercise of the Underwriters' Option to Purchase Additional Shares

Oct 30, 2025, 4:01 PM EDT - 5 months ago

MindMed to Report Q3 2025 Financial Results on November 6, 2025

Oct 29, 2025, 10:14 PM EDT - 5 months ago

Mind Medicine (MindMed) Inc. Announces Pricing of $225 Million Public Offering

Oct 29, 2025, 4:01 PM EDT - 5 months ago

Mind Medicine (MindMed) Inc. Announces Proposed Public Offering

Oct 14, 2025, 12:28 PM EDT - 5 months ago

MindMed Nears Pivotal Year: Strong Fundamentals Make It A Buy

Oct 13, 2025, 2:54 PM EDT - 5 months ago

Mind Medicine Analyst Cites Strong Phase 3 Pipeline For Anxiety, Depression

Sep 19, 2025, 7:00 AM EDT - 6 months ago

New MindMed Retrospective Study Presented at Psych Congress 2025 Reveals High Rates of Suicidal Ideation (SI) in Adults with Generalized Anxiety Disorder (GAD)

Sep 4, 2025, 11:05 AM EDT - 7 months ago

Journal of the American Medical Association (JAMA) Publishes Results from First-Ever Randomized, Placebo-Controlled Clinical Trial Assessing the Dose-Dependent Efficacy of MM120 (Lysergide D-Tartrate, LSD) in Generalized Anxiety Disorder (GAD)

Aug 28, 2025, 7:00 AM EDT - 7 months ago

MindMed to Participate in September Investor Conferences

Jul 31, 2025, 9:48 PM EDT - 8 months ago

Mind Medicine (MindMed) Inc. (MNMD) Q2 2025 Earnings Call Transcript

Jul 31, 2025, 4:01 PM EDT - 8 months ago

MindMed Reports Q2 2025 Financial Results and Business Updates

Jul 24, 2025, 7:00 AM EDT - 8 months ago

MindMed to Report Second Quarter 2025 Financial Results on July 31, 2025

May 28, 2025, 7:00 AM EDT - 10 months ago

MindMed to Participate in June Investor Conferences

May 27, 2025, 7:00 AM EDT - 10 months ago

MindMed Strengthens Executive Team with Appointment of Brandi Roberts, CPA, as Chief Financial Officer

May 13, 2025, 7:00 AM EDT - 11 months ago

MindMed to Present at the 2025 RBC Capital Markets Global Healthcare Conference

May 8, 2025, 9:55 AM EDT - 11 months ago

Mind Medicine (MindMed) Inc. (MNMD) Q1 2025 Earnings Call Transcript

May 8, 2025, 7:00 AM EDT - 11 months ago

MindMed Reports First Quarter 2025 Financial Results and Recent Business Updates

Apr 24, 2025, 7:00 AM EDT - 11 months ago

MindMed to Report First Quarter 2025 Financial Results on May 8, 2025

Apr 15, 2025, 7:00 AM EDT - 1 year ago

MindMed Announces First Patient Dosed in Phase 3 Emerge Study of MM120 in Major Depressive Disorder (MDD)

Mar 17, 2025, 7:00 AM EDT - 1 year ago

MindMed Appoints Matt Wiley as Chief Commercial Officer

Mar 6, 2025, 12:10 PM EST - 1 year ago

Mind Medicine (MindMed) Inc. (MNMD) Q4 2024 Earnings Call Transcript

Mar 6, 2025, 7:00 AM EST - 1 year ago

MindMed Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Updates

Mar 4, 2025, 7:00 AM EST - 1 year ago

MindMed to Present at Leerink's Global Healthcare Conference 2025

Feb 20, 2025, 7:00 AM EST - 1 year ago

MindMed to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025

Feb 4, 2025, 7:00 AM EST - 1 year ago

MindMed to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Jan 30, 2025, 7:00 AM EST - 1 year ago

MindMed Announces First Patient Dosed in Panorama, the Second Pivotal Phase 3 Study of MM120 in Generalized Anxiety Disorder

Dec 19, 2024, 7:00 AM EST - 1 year ago

MindMed to Be Added to the Nasdaq Biotechnology Index

Dec 16, 2024, 7:00 AM EST - 1 year ago

MindMed Announces First Patient Dosed in Phase 3 Voyage Study of MM120 in Generalized Anxiety Disorder (GAD)

Dec 11, 2024, 7:00 AM EST - 1 year ago

MindMed Scientific Presentations at American College of Neuropsychopharmacology (ACNP) 2024 Congress

Dec 5, 2024, 7:00 AM EST - 1 year ago

MindMed Awarded Innovation Passport Designation by the United Kingdom (UK) Innovative Licensing and Access Pathway (ILAP) Steering Group for MM120 Orally Disintegrating Tablet (ODT) for Generalized Anxiety Disorder (GAD)

Dec 3, 2024, 7:00 AM EST - 1 year ago

MindMed Appoints Javier Muniz, M.D., as Vice President of Research and Development Strategy

Nov 18, 2024, 7:00 AM EST - 1 year ago

MindMed Appoints Gregg Pratt, Ph.D. as Chief Regulatory and Quality Assurance Officer

Nov 10, 2024, 9:55 AM EST - 1 year ago

Mind Medicine: No News = Good News

Nov 7, 2024, 8:06 PM EST - 1 year ago

Mind Medicine (MindMed) Inc. (MNMD) Q3 2024 Earnings Call Transcript

RarelyRight Mar. 20 at 5:10 PM

$DFTX Wondering if I should trim and move to $CMPS or $ATAI.

4 · Reply

ZackScott Mar. 20 at 4:02 PM

$DFTX

0 · Reply

CuriousChimps Mar. 20 at 4:01 PM

$DFTX tank part 2

0 · Reply

BobbyCucumber Mar. 20 at 2:47 PM

$DFTX

0 · Reply

rajin11 Mar. 19 at 7:50 PM

$DFTX over or under $19 this friday?

1 · Reply

Horseman23 Mar. 19 at 7:36 PM

$DFTX

0 · Reply

CuriousChimps Mar. 19 at 6:22 PM

$DFTX tank

1 · Reply

Rocketzz Mar. 19 at 4:48 PM

$DFTX immune from market conditions. Someone has been absolutely stacking these shares the past year. Big things to come

2 · Reply

rajin11 Mar. 19 at 2:49 PM

$DFTX what is max pain here? Trying to learn any good sites?

1 · Reply

stoxx0007 Mar. 19 at 1:37 PM

$DFTX $ATAI $CMPS

0 · Reply

twiggs462 Mar. 19 at 1:30 PM

$DFTX $ATAI $CMPS Ukraine's Other Battle: Healing the Invisible Wounds of War Ukraine's therapists seek ways to fund trials of psychedelics despite huge hurdles. https://www.psychologytoday.com/us/blog/patient-revolution/202603/ukraines-other-battle-healing-the-invisible-wounds-of-war

0 · Reply

navle Mar. 18 at 5:51 PM

$CMPS $ATAI $DFTX $HELP In the field of psychedelic medicine, I don't think they're worried about the competition coming from $IXHL

1 · Reply

Apes_Strong Mar. 18 at 3:26 PM

$ATAI $CMPS $DFTX $HELP anything else from the commentary ? Or Q and a ?

1 · Reply

SuperGreenToday Mar. 18 at 3:24 PM

$DFTX Share Price: $17.51 Contract Selected: Jul 17, 2026 $20 Calls Buy Zone: $2.55 – $3.15 Target Zone: $4.30 – $5.26 Potential Upside: 59% ROI Time to Expiration: 120 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

Hindsight1989 Mar. 18 at 3:02 PM

$CMPS $ATAI $DFTX $HELP Kabir Nath, CEO of CMPS today: "we are heads down, focused on executing. We are focused on the competition at launch, which is Spravato. Yeah, we're not focused on the theoretical, yet to be proven, vague, and not very tolerable competition that might be coming behind." Strong words from CMPS. Market hasn't been buying what CMPS is selling, but I think the market is getting it wrong. I still believe CMPS is the most undervalued relative to the risks and opportunity, and will significantly re-rate in the next 9-12 months.

1 · Reply